8-K: Cytek Biosciences Reports Solid Q4 and Full Year 2023 Results, Provides 2024 Outlook

Cytek Biosciences announced a 21% increase in fourth-quarter revenue and an 18% increase in full-year revenue for 2023, alongside a positive outlook for 2024.

Summary

• Cytek Biosciences reported a total revenue of $58.6 million for the fourth quarter of 2023, a 21% increase year-over-year, or 14% on a constant currency basis.
• Organic revenue for the fourth quarter was $48.8 million, a 1% increase compared to the same period in 2022.
• Full-year 2023 total revenue reached $193.4 million, an 18% increase over 2022, or 13% on a constant currency basis.
• Organic revenue for the full year was $164.7 million, which was flat compared to 2022.
• The company placed 152 organic instruments in Q4 and 478 for the full year, expanding the total installed base to 2,148 instruments.
• Cytek repurchased 5,332,769 shares of common stock in Q4 at a cost of $34.7 million, and a total of 6,613,780 shares for $44.2 million since May 2023.
• Gross profit for Q4 was $33.7 million, with a margin of 57%, while adjusted gross profit margin was 60%.
• Full-year gross profit was $110.1 million, with a margin of 57%, and an adjusted gross profit margin of 59%.
• Operating expenses for the full year were $136.8 million, a 33% increase from 2022.
• Net income for Q4 was $6.3 million, compared to $3.7 million in Q4 2022, while the full year resulted in a net loss of $11.3 million compared to a net income of $2.5 million in 2022.
• Adjusted EBITDA for Q4 was $11.0 million, and for the full year was $13.7 million.
• Cytek expects 2024 revenue to be between $203 million and $213 million, representing 5% to 10% growth, and anticipates positive net income for the year.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong revenue growth and a positive outlook for 2024, but tempered by decreased margins and a net loss for the full year 2023. The company is taking steps to improve profitability and operational efficiency.

Positives

• Total revenue for the fourth quarter of 2023 increased by 21% year-over-year.
• Full-year 2023 total revenue increased by 18% compared to 2022.
• The company achieved positive net income in the fourth quarter of 2023.
• Cytek expects to report positive net income for the full year 2024.
• The company successfully integrated the Luminex flow cytometry and imaging business.
• Cytek expanded its global footprint with 478 organic instrument placements in 2023.
• The company launched the Cytek Orion smart cocktail reagent mixer.
• Customer adoption of Cytek Cloud has surpassed expectations with over 6,000 users.
• Cytek received ISO 13485 Quality Management System Certification for its headquarters and manufacturing operations.
• The company has a strong cash position of $262.7 million as of December 31, 2023.

Negatives

• Organic revenue growth was only 1% in the fourth quarter of 2023.
• Full-year organic revenue was flat compared to 2022.
• Gross profit margin decreased from 61% to 57% in Q4 2023.
• Full-year gross profit margin decreased from 62% to 57% in 2023.
• Operating expenses increased by 33% for the full year 2023.
• The company reported a net loss of $11.3 million for the full year 2023.
• Adjusted EBITDA decreased from $21.2 million in 2022 to $13.7 million in 2023.
• Cash reserves decreased by $81.3 million from the end of 2022.

Risks

• The company faces challenges from dynamic macroeconomic market conditions.
• There is a risk of lower product gross margins due to higher material and acquisition costs.
• The company's growth is dependent on customer demand and adoption of its products.
• Cytek is subject to competition in the cell analysis market.
• The company needs to manage the growth and complexity of its organization.
• Cytek must maintain relationships with customers and suppliers and retain key employees.
• The company needs to protect and enhance its intellectual property.
• Cytek must stay in compliance with material contractual obligations, laws, and regulations.

Future Outlook

Cytek expects total revenue for 2024 to be in the range of $203 million to $213 million, representing 5% to 10% growth, and anticipates reporting positive net income for the full year.

Management Comments

• We delivered strong fourth quarter performance amidst a challenging macro-economic environment.
• Our teams navigated well while executing our business strategy, and we took actions to ensure that we remain an agile organization.
• As we look ahead to 2024, we remain laser focused on effectively driving strategic growth and delivering long-term profitability.
• Cytek remains on the forefront of innovation and industry leadership, and we are excited for the large opportunities ahead.
• We are committed to improving these metrics going forward.
• We are reiterating our long-standing commitment to operating the business profitably on an annual basis, as measured by adjusted EBITDA.

Industry Context

Cytek operates in the cell analysis solutions market, which is experiencing a 6% to 8% growth rate. The company's performance is being impacted by macroeconomic conditions and the integration of the Luminex acquisition. Cytek is focused on expanding its market share and driving growth through innovation and strategic partnerships.

Comparison to Industry Standards

• Cytek's revenue growth of 18% for the full year 2023 significantly outpaced the estimated 6-8% growth rate of the overall flow cytometry market.
• While Cytek's organic growth was flat for the year, the Luminex acquisition contributed to the overall revenue increase.
• Competitors in the cell analysis space include companies like BD Biosciences, Thermo Fisher Scientific, and Danaher, which also offer flow cytometry and related technologies.
• Cytek's focus on full spectrum profiling (FSP) technology differentiates it from some competitors, offering higher multiplexing capabilities.
• The company's adjusted EBITDA of $13.7 million for the year is a key metric for comparison against peers, though some competitors may have higher profitability due to scale or different business models.
• Cytek's gross profit margin of 57% is lower than some industry benchmarks, indicating potential for improvement through cost optimization and product mix adjustments.

Stakeholder Impact

• Shareholders will be impacted by the company's financial performance and future growth prospects.
• Employees will be affected by the company's restructuring and cost-cutting measures.
• Customers will benefit from the company's innovative products and solutions.
• Suppliers will be impacted by the company's purchasing decisions.
• Creditors will be impacted by the company's financial stability and debt management.

Next Steps

• Cytek will continue to focus on driving revenue growth, margin expansion, and capital efficiency.
• The company will make prudent investments into growth to position itself as a leader in flow cytometry.
• Cytek is evaluating opportunities to accelerate revenue growth through M&A and other corporate development actions.
• The company will continue to deepen customer relationships to drive greater adoption and utilization of Cytek cell analysis solutions.
• Cytek will continue to monitor and respond to macroeconomic conditions.

Key Dates

Keywords

cell analysis, flow cytometry, revenue growth, financial results, instrument placements, reagent, EBITDA, gross margin, Cytek Aurora, Northern Lights, Cytek Orion, Luminex, Amnis, Guava